IPO - MediWound Ltd.

Form Type: F-3

Filing Date: 2025-03-19

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000949

Filing Summary: MediWound Ltd. filed a registration statement with the SEC under Form F-3 on March 19, 2025. The document indicates an upcoming public offering of $125,000,000 worth of securities, including ordinary shares, warrants, and debt securities. The ordinary shares are to be offered by both the company and a selling shareholder, specifically entities affiliated with Clal Biotechnology Industries, which plans to offer up to 1,266,141 ordinary shares. The document details that the closing price of the ordinary shares was reported as $19.27 on March 18, 2025, on the Nasdaq Global Market under the symbol “MDWD.” MediWound is known for its advanced enzymatic therapeutics focused on wound care with flagship products such as NexoBrid and ongoing development of EscharEx, a pipeline drug for chronic wound treatment. The offering is part of a shelf registration process that allows the company to offer securities from time to time as needed for general corporate purposes, such as product development and commercialization.

Document Link: View Document